Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
95201 trials found · Page 158 of 4761
-
New drug aims to shield cancer patients from chemo side effects
Disease control Not yet recruitingThe goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is: Does trilaciclib have a myeloprotective effect in subject with limited stage small c…
Phase: PHASE3 • Sponsor: Pharmacosmos A/S • Aim: Disease control
Last updated May 16, 2026 15:25 UTC
-
Mind-Reading device aims to give voice to the voiceless
Disease control Recruiting nowThe Connect-One Study is an early feasibility study to obtain preliminary device safety information for the Connexus Brain-Computer Interface (BCI). The Connexus BCI is intended to be used as: (1) an assistive communication device to decode imagined language correlates and speech…
Phase: NA • Sponsor: Paradromics • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Stomach cancer shot could replace IV drip in major trial
Disease control Not yet recruitingA Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for PAD patients: experimental drugs aim to stop deadly clots after leg surgery
Disease control Not yet recruitingThis study is researching 2 different experimental drugs called REGN7508 and REGN9933. The study is focused on people who have Peripheral Artery Disease (PAD), which means that the blood vessels in their arms and legs have become too narrow. People with PAD have a higher risk of …
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 16, 2026 15:22 UTC
-
New hope for aggressive lymphoma: targeted combo trial launches
Disease control Not yet recruitingEvaluate the efficacy and safety of C Pola R-CHP+X compared to CR-CHOP in the treatment of previously untreated patients with DEL
Phase: PHASE3 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated May 16, 2026 15:22 UTC
-
New light therapy combo shows promise for tough bile duct cancer
Disease control Recruiting nowStudy Design: Multicenter, open-label, Single Group Study Population: Patients with locally advanced or recurrent metastatic extrahepatic cholangiocarcinoma who are inoperable or unwilling to undergo surgery. Primary Research Objective: To preliminarily evaluate the efficacy of …
Phase: PHASE2 • Sponsor: Shanghai Guangsheng Biopharmaceutical Co., Ltd • Aim: Disease control
Last updated May 04, 2026 16:30 UTC
-
New drug duo targets deadly brain TB in early trial
Disease control Not yet recruitingAlpE is a novel drug combination under development for the treatment of TB, with several positive attributes for TBM, including rapid bactericidal activity. The current trial aims to assess the plasma and CSF PK, as well as the safety and tolerability of alpibectir and three dose…
Phase: PHASE2 • Sponsor: BioVersys AG • Aim: Disease control
Last updated May 08, 2026 12:03 UTC
-
Can a heart drug help beat breast cancer? new trial aims to restore immunotherapy power
Disease control Not yet recruitingThis phase II trial tests how well propranolol and pembrolizumab work to cause tumor re-sensitization and therefore treatment in patients with triple negative breast cancer that has not responded to previous checkpoint inhibitor therapy (refractory), cannot be removed by surgery …
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
ERs to offer instant HIV prevention pills in bold new trial
Prevention Not yet recruitingOur primary objective is to increase HIV pre-exposure prophylaxis (PrEP) awareness and uptake among people who want, need, or would benefit from PrEP in Dallas, TX through a pilot program of immediate PrEP prescribing in the Parkland Memorial Hospital Emergency Department (ED) wi…
Phase: NA • Sponsor: University of Texas Southwestern Medical Center • Aim: Prevention
Last updated May 14, 2026 12:04 UTC
-
Could zapping the main tumor boost survival in widespread lung cancer?
Disease control Not yet recruitingFor patients with non-small cell lung cancer and more than five metastatic lesions (non-oligometastatic disease), does radical treatment of the primary lung lesion, in addition to pharmacotherapy, also provide benefits in terms of progression-free survival (PFS) and local control…
Phase: NA • Sponsor: Guizhou Medical University • Aim: Disease control
Last updated May 16, 2026 15:25 UTC
-
Brain chip could restore arm movement after stroke
Disease control Not yet recruitingThe clinical investigation will take place in three phases: * A pre-selection/selection phase to ensure that the patient (lesion, symptoms, ability of our tools to detect your movement intentions, etc.) is suitable for a six-month intensive rehabilitation program using Brain-Mac…
Phase: NA • Sponsor: University Hospital, Grenoble • Aim: Disease control
Last updated May 16, 2026 15:27 UTC
-
New drug cocktail aims to wipe out stomach cancer before surgery
Disease control Not yet recruitingThis study is a prospective, randomized, open, multicenter phase II clinical trial. It plans to enroll 70 participants with locally advanced gastric and gastroesophageal junction adenocarcinoma (G/GEJ AC) who are assessed as suitable for D2 radical surgery and capable of R0 resec…
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated May 16, 2026 15:27 UTC
-
New monkeypox vaccine JT118 enters first human safety trial
⭐️ VACCINE ⭐️ Not yet recruitingThis study is a randomized, double-blind, placebo-controlled Phase I clinical trial representing the first-in-human (FIH) investigation of the Monkeypox recombinant protein vaccine JT118. The primary objectives are to evaluate the safety, tolerability, and immunogenicity of two d…
Phase: PHASE1 • Sponsor: Shanghai JunTop Biosciences Co., LTD • Aim: ⭐️ VACCINE ⭐️
Last updated May 11, 2026 20:50 UTC
-
New Dual-Action drug shows promise in lung cancer fight
Disease control Recruiting nowEligible untreated participants with Extensive Stage Small Cell Lung Cancer (ES-SCLC) who are ≥ 18 years of age will be randomized to receive ivonescimab 10 milligrams per kilogram (mg/kg) or ivonescimab 20 mg/kg in combination with carboplatin and etoposide. Ivonescimab is a ty…
Phase: PHASE2 • Sponsor: PrECOG, LLC. • Aim: Disease control
Last updated May 16, 2026 15:25 UTC
-
One-Week radiation for breast cancer lymph nodes could replace Three-Week standard
Disease control Not yet recruitingFor patients with breast cancer, regional nodal irradiation (RNI) can significantly reduce the risks of recurrence and mortality. Moderate hypofractionated regimens (40 to 42.5 Gy in 15 to 16 fractions over 3 weeks) is the established standard of care for RNI. Nevertheless, for t…
Phase: NA • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated May 16, 2026 15:23 UTC
-
New combo aims to crush leukemia in first strike
Disease control Recruiting nowThis phase II trial tests the effect of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) with or without rituximab plus ponatinib in treating patients newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leu…
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for prostate cancer: could a short hormone boost stop spread?
Disease control Recruiting nowThe goal of this study is to determine whether the addition of Androgen Deprivation Therapy (ADT) utilizing the study drug ELIGARD® to Recurrence- Directed Therapy (RDT) improves progression-free survival (PFS) compared to RDT alone in patients with early radio-recurrent oligo-me…
Phase: PHASE2 • Sponsor: Ontario Clinical Oncology Group (OCOG) • Aim: Disease control
Last updated May 16, 2026 15:22 UTC
-
New blood filter aims to curb organ failure in pancreatitis patients
Disease control Recruiting nowThe goal of the study is to evaluate the safety and efficacy of multimodal (cytokine and lipopolysaccharide) hemoperfusion using the Efferon® LPS device in combination with hemofiltration (HF) / hemodiafiltration (HDF), with the goal of reducing the severity of organ dysfunction …
Phase: NA • Sponsor: Efferon JSC • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for rare lung infection: drug trial targets stubborn bacteria
Disease control Recruiting nowThis double-blind, randomized, placebo-controlled, parallel-group, multicenter, prospective, investigator-initiated trial will evaluate epetraborole (EBO) monotherapy in the treatment of adults with Mycobacterium abscessus complex (MABc) Lung Disease (LD) of mild to moderate seve…
Phase: PHASE2 • Sponsor: Kevin Winthrop • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New drug duo shows promise in shrinking lung tumors before surgery
Disease control Recruiting nowThe aim of the study to evaluate the safety and efficacy of Sacituzumab Tirumotecan in combination with osimertinib or as monotherapy for neoadjuvant treatment in patients with resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer.
Phase: PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 16, 2026 15:24 UTC